fashion -WSS

fashion

author：fashion 2025-10-01 15:39:44 - browse：53427

Travere Therapeutics said Thursday that a study meant to confirm the benefit of its newly approved drug for a rare kidney disorder narrowly failed.

In the trial, 404 patients with the disorder, IgA nephropathy, were randomized to receive either Travere’s daily pill, Filspari, or irbesartan, a decades-old blood pressure drug often used to help manage the disease. Early data had showed the drug cut protein levels in the urine, a biomarker of kidney function, by half after nine months. That convinced regulators to give Filspari accelerated approval in February, pending full results using a more direct measure of kidney function.

The new data, after 24 months, showed that patients who received Filspari declined less quickly than those in the control group. But the results just missed statistical significance, with a P value of 0.058.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Study suggests new cause of Down syndrome: cells linked to aging

WSS

Rune Labs, whose app tracks Parkinson's symptoms, raises $12M

Trader Joe's recalls 10K cases of broccoli cheddar soup over potential foreign material

Stories you might have missed in 2023: health, science, medicine

Nonprofit, backed by Microsoft, to certify AI tools in health care

Physician assistants need a new name. Here's what it should be

Ford recalls 870K F

entertainment

fashion

knowledge

After affirmative action ruling, medical educators look to 'holistic review'

Marc Tessier

Medicare details structure of new drug price negotiation program

FDA early review: GLP

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Trump lawyers meet with special counsel in Jan. 6 case as potential indictment looms

At least 13 dead in Texas as scorching temps continue

Interest rates are at a 22

How one medical school became remarkably diverse

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

leisure time

Biden jokes that Republicans may impeach him because inflation is starting to cool down

At JPM 2024, hospital systems pitch financial strength to investors

Ending health disparities requires full federal government, panel says

‘We were in the air.’ Mississippi family recounts surviving tornado that tore mobile home apart

JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

Hospitals, health systems can help patients avoid medical debt

hotspot

entertainment

entertainment

explore